NumFin

Sarepta Therapeutics, Inc.

Sümbol: SRPT

NASDAQ

130.63

USD

Turuhind täna

  • 726.6405

    P/E suhe

  • -300.6475

    PEG suhe

  • 12.35B

    MRK Cap

  • 0.00%

    DIV tootlus

Sarepta Therapeutics, Inc. (SRPT) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete Sarepta Therapeutics, Inc. (SRPT) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 153.75 M, mis on 5.127 % gowth. Kogu perioodi keskmine brutokasum on 119.498 M, mis on 5.178 %. Keskmine brutokasumi suhtarv on -3.321 %. Ettevõtte eelmise aasta tulemuse puhaskasv on -0.238 %, mis on võrdne -2.304 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes Sarepta Therapeutics, Inc. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus 0.044. Käibevara valdkonnas on SRPT aruandlusvaluutas 2579.331. Märkimisväärne osa neist varadest, täpsemalt 1676.25, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust -0.157%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 22.106, kui neid on, aruandlusvaluutas. See näitab erinevust -29.421% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 1132.515 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on -0.136%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 859.337 aruandlusvaluutas. Selle aspekti aastane muutus on 1.232%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 439.706, varude hind on 322.86 ja firmaväärtus 0, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 29.62. Kontovõlad ja lühiajalised võlad on vastavalt 164.92 ja 123.33. Koguvõlg on 1396.81, netovõlg on 968.38. Muud lühiajalised kohustused moodustavad 315, mis lisandub kohustuste kogusummale 2405.24. Lõpuks hinnatakse viidatud aktsia 0, kui see on olemas.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

balance-sheet.row.cash-and-short-term-investments

6661.251676.31989.42115.9
1938.6
1124.7
1173.9
1079.1
317.8
192.5
210.3
257
187.7
39.9
33.6
48.4
11.5
25.1
33.2
47.1
19.5
37.6
19.3
25.6
32.1
11.6
8.5
17.6
3
0.9

balance-sheet.row.short-term-investments

4411.671247.81022.60
435.9
289.7
803.1
479.4
195.4
112.2
136.8
0
0
0
0
0.2
0.3
0.3
13
12.5
2.9
25.1
8.9
14.5
6.2
2.9
0
0
0
0.2

balance-sheet.row.net-receivables

1480.51439.7259.7171.6
138.6
93.9
49
29.5
5.2
4
2.4
3.5
4.7
3.6
3.2
2.1
5
2.9
0.1
1.2
0
0
0.5
1.7
0
0
0
0
0
0

balance-sheet.row.inventory

1167.28322.9204186.2
232
171.4
125.4
83.6
12.8
26.9
33.5
7.3
0
-3.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

446.86140.57.76.1
4.1
5.2
77.8
36.5
0.9
1.2
1.6
3.1
1.5
5.3
1
0.8
0.6
0.8
0.7
0.4
0.7
0.8
0.6
0.2
1
0.1
0.5
0.1
0
0

balance-sheet.row.total-current-assets

9967.662579.32557.92604.1
2485.2
1468.9
1426.2
1228.6
373.5
224.5
247.8
270.8
193.9
45.2
37.8
51.3
17
28.7
33.9
48.7
20.2
38.4
20.4
27.5
33.1
11.7
9
17.7
3
0.9

balance-sheet.row.property-plant-equipment-net

1402.1357.1245236.7
282.2
167.6
97
43.2
37.8
37.3
38.5
15
3.4
4.3
4
2.5
5.2
6.8
4.3
5.6
6.3
7
6.6
4.9
1
0.4
0.4
0.4
0.5
0.9

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

67.1429.67.614.2
13.6
12.5
11.6
14.4
8.1
6.6
5.9
5
4.9
4.8
4
3.8
3.3
3.1
2.6
2.1
2
1.7
1.6
1.4
0.9
0.8
0.7
0.6
0
0.4

balance-sheet.row.goodwill-and-intangible-assets

67.1429.67.614.2
13.6
12.5
11.6
14.4
8.1
6.6
5.9
5
4.9
4.8
4
3.8
3.3
3.1
2.6
2.1
2
1.7
1.6
1.4
0.9
0.8
0.7
0.6
0
0.4

balance-sheet.row.long-term-investments

66.5522.131.334.9
38.8
31.9
107.3
10
0.8
0.8
0
0.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

166.7400114.8
151.9
130.1
-107.3
-10
-0.8
-0.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

1054.37276.4286.6143.3
13
11.8
107.3
21.8
4
4.5
2.8
0
2.8
0.2
0.1
2.5
0
0
0
0
0
0
0
0
0
0
0.1
0.1
0.7
0.1

balance-sheet.row.total-non-current-assets

2756.9685.2570.5543.9
499.5
353.9
215.9
79.3
50.6
49.2
47.2
20.8
11.1
9.2
8.1
8.7
8.5
9.9
6.9
7.8
8.3
8.8
8.2
6.3
2
1.2
1.2
1.1
1.2
1.4

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

12724.563264.63128.43148
2984.7
1822.8
1642.1
1308
424.1
273.8
295
291.6
205
54.4
46
60
25.5
38.6
40.9
56.4
28.5
47.1
28.6
33.8
35.1
12.9
10.2
18.8
4.2
2.3

balance-sheet.row.account-payables

454.2164.995.976.7
111.1
68.1
33.8
8.5
29.7
20.2
12.4
17.6
7.5
9.4
1.3
1.4
2
3
1.4
1.9
1.5
3.1
4.5
2.8
1.3
0.7
0.9
0.2
0.2
0.1

balance-sheet.row.short-term-debt

878.14123.315.5271.7
193.6
7.8
134.1
6.2
10.1
8.4
2.6
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-payables

77.5513.812.50.2
0
0
0.3
0.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

5002.371132.51601.91138.4
1072.9
729.6
420.6
424.9
6
15
3.7
1.6
1.7
1.8
1.8
1.9
2
2.1
0
0
0
0
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

1732437485574.2
663.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

281.07---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

649.5331541915.1
22.1
196.7
2.5
70.4
32.3
30.3
18.6
14.9
68
7.8
41.2
28.6
3
5.9
1.7
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.3
0.3
0.1
0.2

balance-sheet.row.total-non-current-liabilities

7186.51751.62123.81767.2
1806.9
739.9
436.1
430.4
12
21.1
10.5
8.4
2.4
2.8
2.9
2.9
2.5
2.5
0
0
0
0
0
0
0
0
0
0
3.1
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

561.2614173.141.5
80.4
47.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

9398.262405.22743.42220
2223
1004.6
609.8
518.7
87.4
83.4
47.4
44.4
81.3
23.4
48.8
36.4
9.8
12.3
3.2
2.7
2.2
3.8
5.1
3.3
1.7
1
1.2
0.5
3.4
0.3

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
0
0
0
0
0

balance-sheet.row.common-stock

0.04000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3.1

balance-sheet.row.retained-earnings

-17799.11-4446.2-3910.2-3206.7
-2848.1
-2294
-1578.9
-1217
-1166.3
-899.1
-679
-543.2
-431.3
-310
-307.6
-275.5
-250.3
-226.4
-203.7
-172.6
-156
-131.2
-116.6
-87.2
-60.3
-51.1
-42.8
-16
-12.4
-10.3

balance-sheet.row.accumulated-other-comprehensive-income-loss

-1.470.9-1.70
0
0.1
-0.1
-0.4
-0.1
-0.1
-0.1
-17.3
-16.7
-15.8
-15
-14
-12.9
-11.8
0
0
-0.1
-0.3
0.7
1
-11.7
-2.5
-2.4
-2.3
-1.9
0.1

balance-sheet.row.other-total-stockholders-equity

21126.835304.64296.84134.8
3609.9
3112.1
2611.3
2006.6
1503.1
1089.5
926.8
807.8
571.6
356.7
319.8
313.1
279
264.5
241.4
226.3
182.4
174.9
139.3
116.7
96.3
65.5
54.2
36.6
15.1
9.2

balance-sheet.row.total-stockholders-equity

3326.3859.3384.9928
761.8
818.2
1032.3
789.2
336.7
190.3
247.7
247.2
123.7
31
-2.8
23.6
15.7
26.4
37.7
53.7
26.3
43.4
23.5
30.5
33.4
11.9
9
18.3
0.8
2.1

balance-sheet.row.total-liabilities-and-stockholders-equity

12724.563264.63128.43148
2984.7
1822.8
1642.1
1308
424.1
273.8
295
291.6
205
54.4
46
60
25.5
38.6
40.9
56.4
28.5
47.1
28.6
33.8
35.1
12.9
10.2
18.8
4.2
2.4

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

3326.3859.3384.9928
761.8
818.2
1032.3
789.2
336.7
190.3
247.7
247.2
123.7
31
-2.8
23.6
15.7
26.4
37.7
53.7
26.3
43.4
23.5
30.5
33.4
11.9
9
18.3
0.8
2.1

balance-sheet.row.total-liabilities-and-total-equity

12724.56---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

4433.771269.91053.934.9
474.7
321.6
803.1
489.3
195.4
112.2
136.8
0.6
0
0
0
0.2
0.3
0.3
13
12.5
2.9
25.1
8.9
14.5
6.2
2.9
0
0
0
0.2

balance-sheet.row.total-debt

5512.351396.81617.41138.4
1072.9
729.6
420.6
431.1
16.1
23.4
6.3
1.7
1.8
1.8
1.9
2
2.1
2.1
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-debt

3262.77968.4650.6-977.5
-429.8
-105.5
49.7
-168.6
-106.3
-56.9
-67.2
-255.3
-185.9
-38.1
-31.7
-46.3
-9.1
-22.7
-20.2
-34.6
-16.7
-12.5
-10.4
-11.1
-25.9
-8.7
-8.5
-17.6
-3
-0.7

Rahavoogude aruanne

Sarepta Therapeutics, Inc. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab -0.652 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 51.25, mis tähistab 0.000 erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli -165803000.000. See on -0.842 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 58.89, 102, -73.76, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte 0 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui 147.52, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

cash-flows.row.net-income

16.9-536-703.5-418.8
-554.1
-715.1
-361.9
-50.7
-267.3
-220
-135.8
-112
-121.3
-2.3
-32.2
-25.2
-24
-27.2
-31.1
-16.7
-24.8
-14.6
-29.4
-26.9
-9.2
-8.3
-26.7
-3.6
-2.1
-2.6

cash-flows.row.depreciation-and-amortization

49.6558.941.938
26.9
30.5
12.2
8.1
5.6
5.2
3.7
1.3
1.5
1.3
1.5
1.4
1.5
2
2.1
2
1.9
1.5
1.3
0.6
0.4
0.3
0.2
0.5
0.5
0.5

cash-flows.row.deferred-income-tax

0383.5015.8
10.6
-8.4
-1.4
-0.1
0.4
0.8
5.3
11.5
0
0.3
1.2
0.5
0.4
-0.3
-0.3
-0.4
-0.4
-0.5
-0.5
-0.1
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

141.26182.5233113.9
108.1
78.6
50.1
30.5
30
32.1
20.3
11.1
3.1
3.1
3.2
2.4
0.2
0.3
0.5
0.4
0.4
0.5
0.5
0.1
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-681.64-481.1-39.5-98.2
554.1
-66.9
-107.9
-97.5
-15.8
32
-22.1
12.3
-5.3
6.9
-0.3
2.9
-2.8
-0.4
1.4
-0.4
-1.4
-1.1
2.6
0.8
-0.3
0.4
0.2
0.1
0.1
0.1

cash-flows.row.account-receivables

-154.97-185.7-61.6-51.6
-10.5
-41.8
-19.6
-24.2
-1.3
-1.6
1.1
2.8
-3.6
-1.1
0
2.6
-1.8
-2.8
0.8
-0.9
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-207.92-147.7-50.8-83.8
-60.6
-45.9
-41.8
-70.8
-12.8
-147
-244.9
-234.8
-115
-24.6
0
-17.8
-9.8
-19
0
-45.9
0
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

-40.43-50.1147.623.3
42
123
90.2
12.9
7.3
18.3
10.8
9.5
-1.7
8
0
0.3
-1
2.5
0.6
0.5
-1.5
1.8
1.8
1.7
0
0
0
0
0
0

cash-flows.row.other-working-capital

-278.32-97.5-74.614
583.1
-102.1
-136.6
-15.4
-9
162.2
210.9
234.8
115
24.6
-0.3
17.8
9.8
19
0
45.9
0.1
-2.9
0.8
-0.9
-0.3
0.4
0.2
0.1
0.1
0.1

cash-flows.row.other-non-cash-items

375.58-108.9142.7-94
-38.1
224.8
20.2
-122.3
1.3
0.4
0
11.1
92.3
-33
11.5
9.2
12.4
0.8
6.8
0.4
0.5
-3.3
5.1
12.8
0
0
19.6
0
-0.1
0.3

cash-flows.row.net-cash-provided-by-operating-activities

-533.67000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-110.3-87.3-30.8-38.5
-82.2
-62.7
-64.3
-21.2
-6.9
-4.8
-26.8
-3.8
-1.1
-2.3
-2
-2
-1.2
-2.1
-1.5
-1.5
-1.1
-1.6
-2.8
-4.2
-0.8
-0.2
-2.3
-0.3
-0.1
-0.3

cash-flows.row.acquisitions-net

0000
0
-172.6
3.2
-9.2
1.5
1.4
1.4
0
0
0
0
0
0
0.9
0.7
0.4
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-1838.63-2048.9-1936.9-30
-1333.6
-1193.6
-1172
-589.5
-195.4
-172.7
-274.4
-7.9
0
0
0
0
0
-0.1
-15
-13.1
-13.1
-44.4
-19.1
-8.1
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

1897.341868.5923.2466
1189.5
1715.6
865.8
306.9
112.1
185.9
142.2
0
0
0
0
0.1
0.9
12.8
14.4
3.7
35.5
31
19.9
0
0
0
0
0
0.2
0

cash-flows.row.other-investing-activites

353.33102-2.497.9
104.6
0
-3.2
134.2
-1.5
-1.4
-1.4
0
0
0
0
0
-0.9
-0.9
-0.7
-0.4
-0.5
-0.4
-0.5
-0.5
-0.3
-0.3
-0.3
-0.2
0
0

cash-flows.row.net-cash-used-for-investing-activites

40.5-165.8-1046.9495.4
-121.7
286.7
-370.5
-178.8
-90.2
8.4
-159
-11.7
-1.1
-2.3
-2
-1.9
-1.2
10.6
-2
-10.9
20.8
-15.5
-2.4
-12.8
-1.1
-0.5
-2.6
-0.5
0.1
-0.3

cash-flows.row.debt-repayment

-157.87-73.8-823.20
-291.1
-244.9
-267.2
-54.8
-7.6
-2.6
-0.1
-0.1
-0.1
-0.1
-0.1
-0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

73.3951.230548.5
312.1
365.4
513.4
354
364.8
130.8
104.2
146
178.7
32.4
2.6
47.8
0.1
18.7
8.2
43.5
7.1
35.1
22
10.8
27.4
8.2
0.2
18.4
4
0

cash-flows.row.common-stock-repurchased

000-7.8
-4.8
-4.3
0
0
0
0
0
0
0
0
0
0
0.2
0.8
0
0
0
0.1
0.1
0.1
0
0
0
-0.3
0
0.9

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

173.24147.51025.720.8
666.2
526.5
284
588.9
20.9
19.6
0
-0.2
0
0
0
0
-0.3
-0.8
0
0
0
-0.1
-0.1
-0.1
0
0
0
0.1
-0.1
0

cash-flows.row.net-cash-used-provided-by-financing-activities

45.35125232.5561.6
682.3
642.6
530.1
888.1
378.1
147.8
104.2
145.7
178.6
32.3
2.5
47.8
0
18.7
8.2
43.5
7.1
35.1
22
10.8
27.4
8.2
0.2
18.2
3.9
0.9

cash-flows.row.effect-of-forex-changes-on-cash

3.573.400
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
9.3
3.5
1.5
0

cash-flows.row.net-change-in-cash

-444.25-538.3-1139.7613.8
668.1
472.8
-229
477.3
42.1
6.8
-183.4
69.3
147.8
6.3
-14.7
37.1
-13.6
4.6
-14.4
17.9
4.1
2.1
-0.7
-14.8
17.2
0.2
0.2
18.2
3.9
-1.2

cash-flows.row.cash-at-end-of-period

2287.75428.4985.82125.5
1511.7
843.6
370.8
599.8
122.4
80.3
73.6
257
187.7
39.9
33.6
48.3
11.2
24.8
20.2
34.6
16.7
12.5
10.4
11.1
25.9
8.7
17.8
21.2
4.6
-1.2

cash-flows.row.cash-at-beginning-of-period

2732.01966.82125.51511.7
843.6
370.8
599.8
122.6
80.3
73.6
257
187.7
39.9
33.6
48.3
11.2
24.8
20.2
34.6
16.7
12.5
10.4
11.1
25.9
8.7
8.5
17.6
3
0.7
0

cash-flows.row.operating-cash-flow

-533.67-501-325.3-443.2
107.5
-456.5
-388.7
-232
-245.8
-149.5
-128.5
-64.7
-29.7
-23.7
-15.2
-8.8
-12.3
-24.7
-20.6
-14.7
-23.8
-17.5
-20.3
-12.8
-9.1
-7.6
-6.7
-3
-1.6
-1.8

cash-flows.row.capital-expenditure

-110.3-87.3-30.8-38.5
-82.2
-62.7
-64.3
-21.2
-6.9
-4.8
-26.8
-3.8
-1.1
-2.3
-2
-2
-1.2
-2.1
-1.5
-1.5
-1.1
-1.6
-2.8
-4.2
-0.8
-0.2
-2.3
-0.3
-0.1
-0.3

cash-flows.row.free-cash-flow

-643.98-588.3-356.2-481.7
25.3
-519.2
-453
-253.2
-252.7
-154.3
-155.4
-68.5
-30.8
-26
-17.2
-10.8
-13.6
-26.8
-22.1
-16.1
-24.9
-19.1
-23
-17
-9.9
-7.8
-9
-3.3
-1.7
-2

Kasumiaruande rida

Sarepta Therapeutics, Inc. tulud muutusid võrreldes eelmise perioodiga 0.333%. SRPT brutokasum on teatatud 1092.99. Ettevõtte tegevuskulud on 1360.82, mille muutus võrreldes eelmise aastaga on 2.377%. Kulud amortisatsioonikulud on 58.89, mis on -0.060% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 1360.82, mis näitab 2.377% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab 0.501% kasvu võrreldes eelmise aastaga. Tegevustulu on -267.82, mis näitab -0.501% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on -0.238%. Eelmise aasta puhaskasum oli -535.98.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

income-statement-row.row.total-revenue

1403.31243.3933701.9
540.1
380.8
301
154.6
5.4
1.3
9.8
14.2
37.3
47
29.4
17.6
21.3
11
0.1
4.8
0.4
1
0.8
0.7
1.3
0.1
0.2
0.1
0.1
0.1

income-statement-row.row.cost-of-revenue

165.88150.314097
63.4
56.6
34.2
7.4
0.1
146.2
94.1
90.3
51.9
35.9
27.5
0
0
0
0
0
0
0
0
0
-0.4
0
-0.2
-0.5
-0.5
0

income-statement-row.row.gross-profit

1237.411093793604.8
476.7
324.2
266.8
147.2
5.3
-144.9
-84.3
-76.1
-14.6
11.1
2
17.6
21.3
11
0.1
4.8
0.4
1
0.8
0.7
1.7
0.1
0.4
0.6
0.6
0.1

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

826.06---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

589.63---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

-218.47---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

194.841.60.70.7
0.7
0.8
-0.7
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.4
0
0.2
0.5
0.5
0

income-statement-row.row.operating-expenses

1325.71360.81329.21054.5
1040.9
846.6
610.5
290.4
272
221.4
143.5
104.5
67
82.9
50.4
33.1
38.8
44.1
33.1
22.3
25.5
19.8
26.2
16.1
12
8.4
8.1
4.5
2.8
2.7

income-statement-row.row.cost-and-expenses

1498.131511.21469.21151.6
1104.3
903.2
644.7
297.8
272.2
221.4
143.5
104.5
67
82.9
50.4
33.1
38.8
44.1
33.1
22.3
25.5
19.8
26.2
16.1
11.5
8.4
7.9
4
2.3
2.7

income-statement-row.row.interest-income

-19.328616.50.4
3
7.2
6.8
1.8
0
0
0
0
0
0.7
0
0
0
0
1.9
0.8
0
0.5
0
0
1
0
0
0
0
0

income-statement-row.row.interest-expense

-6.322253.263.5
59.9
30.7
33.7
5.8
-0.5
0
0
0.3
0
0.1
0.3
0.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

-218.47---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

143.01-252.3-153.830.8
11.1
-191.6
10.1
96.6
-2.5
0.2
-2.8
-22
-91.9
33
-11.5
-9.2
-6.8
5
1.9
0.8
0.3
3.8
-4.5
-12.5
1
-0.1
-19
0.4
0.2
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

194.841.60.70.7
0.7
0.8
-0.7
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.4
0
0.2
0.5
0.5
0

income-statement-row.row.total-operating-expenses

143.01-252.3-153.830.8
11.1
-191.6
10.1
96.6
-2.5
0.2
-2.8
-22
-91.9
33
-11.5
-9.2
-6.8
5
1.9
0.8
0.3
3.8
-4.5
-12.5
1
-0.1
-19
0.4
0.2
0

income-statement-row.row.interest-expense

-6.322253.263.5
59.9
30.7
33.7
5.8
-0.5
0
0
0.3
0
0.1
0.3
0.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

-17.6458.962.737.6
34.9
52.9
0.9
1.1
5.6
5.2
3.7
1.3
1.5
1.3
1.5
1.4
1.5
2
2.1
2
1.9
1.5
1.3
0.6
0.4
0.3
0.2
0.5
0.5
0.5

income-statement-row.row.ebitda-caps

-73.7---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-94.83-267.8-536.2-449.7
-564.2
-522.3
-343.6
-171.6
-266.7
-220.2
-133.8
-90.3
-29.7
-35.9
-20.9
-15.5
-27.5
-33.1
-33
-17.5
-25
-18.9
-25.3
-15.4
-10.2
-8.3
-7.7
-3.9
-2.2
-2.6

income-statement-row.row.income-before-tax

34.06-520.1-690-418.9
-553.1
-713.9
-362.6
-48.6
-267.3
-220
-135.8
-112
-121.3
-2.3
-24
-24.7
-24
-28.2
-31.1
-16.7
-24.8
-14.6
-29.4
-8.3
-9.2
-8.4
-26.7
-3.5
-2
-2.6

income-statement-row.row.income-tax-expense

17.1615.913.5-0.2
1.1
1.2
-0.7
2.1
-7.6
-5.2
-1.7
20.4
91.6
-34.9
11.2
9.7
6.4
-5.9
0
0
0
-4.3
4
11.5
0
0
19
-0.3
-0.1
0

income-statement-row.row.net-income

16.9-536-703.5-418.8
-554.1
-715.1
-361.9
-50.7
-267.3
-220
-135.8
-112
-121.3
-2.3
-32.2
-25.2
-24
-27.2
-31.1
-16.7
-24.8
-14.6
-29.4
-26.9
-9.2
-8.3
-26.7
-3.6
-2.1
-2.6
Sarnased aktsiad
Sind võib huvitada ka:
SRNE
Sorrento Therapeutics, Inc..
0.014 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
8.8 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.03 USD
NASDAQ
GUBRA.CO
Gubra A/S.
296 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.04 NOK
OSL
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.05 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

Korduma kippuv küsimus

Mis on Sarepta Therapeutics, Inc. (SRPT) koguvara?

Sarepta Therapeutics, Inc. (SRPT) koguvara on 3264576000.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on 810245000.000.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.882.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on -6.851.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on 0.012.

Mis on ettevõtte kogutulu?

Kogutulu on -0.068.

Mis on Sarepta Therapeutics, Inc. (SRPT) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on -535977000.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 1396808000.000.

Mis on tegevuskulude arv?

Tegevuskulud on 1360817000.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 427290000.000.